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Introduction
Gastrointestinal (GI) cancers comprise of gastric, esophageal, 
pancreas, hepatobiliary, colorectal and anal cancers. GI 
cancers to date remain a major cause of cancer related death 
in the US and well as worldwide. Based on the current cancer 
statistics, colorectal, pancreatic, gastric and esophageal 
cancers are third, fourth, fifth and sixth cancer related 
mortality in the US respectively (1). Treatments with surgery, 
chemotherapy, radiation therapy, anti-angiogenic therapy 
have been the mainstay in the treatment of GI cancers, but 
over the last decade novel therapeutics with immunotherapies 
such as cytokines, adaptive cell therapies, peptide- protein- 
or whole-tumor cell or dendritic-cell vaccines and check 
point inhibitors have been evaluated in clinical trials as 
immunomodulatory strategies for GI cancers. 
T cell signaling, activation and antigen recognition
The anti-tumor immune system is composed of innate and 
adaptive immunity. Innate immunity forms the first line of 
defense against tumor cells, whereas adaptive immunity is 
accountable for long-term immune response (2). 
T cells can distinguish a signaling complex comprised 
of a T cell receptor (TCR) dimer, CD8 or CD4 molecules 
and CD3 along with the peptide antigens on the antigen 
presenting cells (APCs) or tumor cells in the presence of 
class I or class II MHC molecules. CD4+ T cells recognize 
class II MHC molecules present on the APC [e.g., 
dendritic cells (DC)] whereas CD8+ T cells recognize class 
I MHC molecules. The T cell activation process requires 
co-stimulatory signals which are provided by binding of 
CD28 on the T cell surface to its ligand B7-1 or B7-2 on the 
APC or tumor cell, as well as binding of intracellular adhesion 
molecule (ICAM) and the leukocyte function associated 
antigen (LFAA) on the APC to their receptors LFA1  and 
CD2, respectively. This co-stimulatory process is regulated 
by binding of cytotoxic T lymphocyte antigen-4 (CTLA-4) 
to B7-1 or B7-2, which acts as a suppressor response also 
called a co-inhibitory process. This step acts as a ‘checkpoint’ 
in the immune response cascade preventing the ‘exhaustion’ 
of T cells (3,4). Figure 1 gives a schematic representation of 
T cell signaling, activation and antigen recognition. Other 
examples of co-stimulatory molecules involved in this 
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Figure 1 T cell signaling, activation and antigen recognition. T cell activation or inhibition is influenced by a dynamic interplay between 
co-stimulatory or co-inhibitory signals between APCs and T cells. Inhibition of the inhibitory PD-1/PD-L1/PD-L2 pathway, and the 
inhibitory CTLA-4 pathway, are currently possible with available therapeutics. APCs, antigen presenting cells; PD-1, programmed death-1; 
PD-L1/PD-L2, program death ligand-1 and 2; CTLA-4, cytotoxic T lymphocyte antigen-4.
process are GITR, OX40 and ICOS. Examples of additional 
co-inhibitory molecules are programmed death-1 (PD-1), 
TIM3 and LAG3. PD-1 is an immune check point receptor 
on the surface of T cell and has two ligands, program death 
ligand-1 and 2 (PD-L1 and PD-L2). Both CTLA-4 and 
PD-1 act independently as immune check point inhibitors (5). 
Immune escape phenomenon in GI cancers
Immune escape is the ability of the cancer cells to escape 
immune responses of the host. Many mechanisms of 
immune escape have been proposed in GI cancers. H. pylori 
have been identified as one of the environmental factors 
leading to gastric cancer. Raghavan et al. have proposed a 
concept of immune modulation by regulatory T cells in 
H. pylori-induced gastric cancers where regulatory T cells 
(Tregs) infiltrate the tumor and promote tumor escape 
from cytotoxic immune responses (6). Many studies have 
proposed an interesting concept for an immune evasive 
mechanism whereby gastric adenocarcinoma cells express 
Fas ligand (FasL) independent of tumor stage that induces 
Fas receptor-mediated apoptosis of activated lymphocytes, 
thus overcoming antitumor immune responses (7,8). Similar 
findings have been found in pancreatic cancer suggesting 
that FasL induces apoptosis of infiltrating lymphoid cells 
in the tumor microenvironment, thereby preventing host 
cytotoxic T cell and natural killer (NK) cell responses (9-11). 
Dysregulation of FasL has also been proposed as an 
immune escape method in biliary tract cancer (12-14).
Expression of B7 family members, co-stimulatory 
molecules on APC or tumor cells, has been shown to be 
involved in a cancer progression/immune surveillance escape 
mechanism. Chen et al. has proposed that ICOS-B7H 
co-stimulatory pathway may be predominant at the site 
of gastric carcinoma (15). A family of B7 molecules has 
also been shown to have an impact on the immune escape 
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phenomenon in colorectal cancers (CRC). Sun et al. studied 
the immunohistochemical expression of B7-H3 pathologic 
specimens from CRC patients. B7-H3 expression was higher 
in cancer tissue as compared to normal colorectal tissue, and 
also correlated with advanced cancer (16). B7-H4 expression 
has been widely studied in pancreatic cancers (17). Qian et al. 
have studied the mechanisms of enhanced oncogenicity and 
inhibition of apoptosis by B7-H4 molecules in pancreatic 
cancer cells and have proposed that B7-H4 is a cancer 
promoter and could potentially be a therapeutic target (18). 
Interestingly, the B7-H1/PD-L1 pathway has been linked 
to the malignant potential of biliary tract cancers causing 
immune escape phenomenon by inducing apoptosis of 
CD8+ tumor infiltrating lymphocytes (19).
A tumor-associated neo-antigen, MUC1 (epithelial 
mucin glycoprotein), has been a target for immunotherapy 
in pancreatic cancer. Monti et al. have proposed that 
tumor-derived MUC1 mucins are immune-inhibitory and 
responsible for impaired DC maturation and function, in 
turn impairing innate immunity (20). Mukherjee et al. have 
shown that MUC1 peptide-based immunization elicits 
mature MUC1-specific CTLs in peripheral lymphoid 
organs, which secrete IFN-γ and are cytolytic against 
MUC1-expressing tumor cells in vitro (21).
Microbiome and immunotherapy 
Significant variability is observed in patient responses to 
immunotherapy, which is not completely understood. 
Recent work using genetically similar mice suggests that 
the gut microbiome may play a significant role in response 
to immunotherapy. A recent study used genetically similar 
B57BL/6 mice obtained from Jackson Labs (JAX) and Taconic 
Farms (TAC), subcutaneously inoculated with a melanoma 
cell line. Upon inoculation, the JAX mouse is found to be 
more tumor-resistant than the TAC mouse. However, when 
the two strains are cohoused prior to tumor inoculation, the 
tumor risk of the TAC mouse is reduced to that of the JAX 
mouse. This effect is reproducible upon fecal transfer from 
the JAX mouse to the TAC mouse, suggesting the presence 
of a tumor-protective effect within JAX mice feces. The 
degree of tumor protection observed with JAX fecal transfer 
into TAC mice is equivalent to the effect of treatment 
of TAC mice with an anti-PD-L1 monoclonal antibody. 
Impressively, the combination of JAX fecal transfer and anti-
PD-L1 treatment resulted in an additive effect in TAC mice, 
showing the most significant tumor growth suppression. 16S 
rRNA sequencing of fecal material, in association with CD8+ 
T cell tumor infiltration, was used to identify which bacterial 
species in JAX feces were associated with improved anti-
tumor immune response. After analysis, Bifidobacterium was 
the only species associated with improved tumor response, 
an effect that was recapitulated after oral gavage of TAC 
mice with Bifidobacterium. The effect of Bifidobacterium 
was eliminated after CD8+ T cell depletion of host mice, 
or after heat-inactivation of the bacteria. Furthermore, 
analysis of spleen and tumor-draining lymph nodes 
demonstrated increased T cell activation due to enhanced 
DC function as the likely underlying mechanism (22). 
Analogous results have been observed in a sarcoma mouse 
model with the anti-CTLA-4 antibody ipilimumab, 
however in this case demonstrating a requirement for 
Bacteroides species. Specifically, anti-tumor efficacy of 
ipilimumab and activation of tumor-infiltrating lymphocytes 
(TIL) is lost in germ-free mice and those treated with 
broad-spectrum antibiotics. Response to anti-CTLA-4 
blockade is restored by enteral administration of Bacteroides 
or by immunization with a Bacteroides vaccine (23). 
These data suggest an intricate relationship between 
host microbial flora and response to immunotherapy, and 
suggest the possibility of manipulating the gut microbiome 
in conjunction with immunotherapy. 
Immune therapies in GI cancers 
Immune therapies in GI cancers comprise checkpoint 
inhibitors, vaccine therapies, cytokines and adaptive cell 
transfer. Currently, checkpoint inhibitors are the most studied 
in the treatment of GI cancers. Figure 2 represents an overview 
of immune therapies in GI cancers. Vaccine, cytokine and 
adaptive cell transfer therapies are not FDA-approved for GI 
cancers but are being studied in clinical trials.
CRC
PD-1 and CTLA-4 based immunotherapy in CRC
The concept of tumor-specific mutations leading to 
tumor-associated neo-antigens is fundamental to tumor 
immunotherapy. A direct prediction of this concept is 
that more highly mutated tumors will have more tumor-
associated neo-antigens, increasing their immunogenicity. 
Accordingly, more highly mutated tumors (melanoma, 
lung, GI and head and neck cancers) are the ones which 
show the greatest responses to immunotherapy (24). 
Furthermore, subsets of tumors with particularly high 
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mutation frequencies, such as mismatch repair (MMR)-
deficient cancers which contain approximately 500-fold 
more mutations per tumor (25), are predicted to be the 
most immunogenic and have the greatest responses to 
immunotherapy.
To date, the PD-1 and CTLA-4 pathways have been the 
most studied in CRC. The PD-1 pathway is an immune-
inhibitory checkpoint pathway that when activated 
suppresses cytotoxic T cell responses. The PD-1 receptor 
is expressed on the surface of T cells and has two ligands 
(PD-L1 and PD-L2), which are predominantly expressed 
on malignant cells and APCs. Pembrolizumab and 
nivolumab are fully human IgG4 anti-PD-1 monoclonal 
antibodies (mAbs) that disrupt the PD-1 pathway. The 
CTLA-4 pathway serves a similar inhibitory role. CTLA-4 
is a cell-surface receptor on T cells that, when engaged by 
B7-1 or B7-2 on an APC, inhibits T cell activation thereby 
facilitating tumor immune escape. Ipilimumab (a human 
IgG1 mAb) was the first approved anti-CTLA-4 mAb and is 
the prototype member of this class. 
A recent phase 2 trial was designed to evaluate the 
efficacy of pembrolizumab in MSI-high and MSI-low 
colorectal and non-CRC. Patients with previously treated 
metastatic colorectal or non-CRC were treated with 
pembrolizumab 10 mg/kg every 2 weeks, stratified by MSI 
status. All tumor responses were partial, and were only seen 
in MSI-high tumors. Similarly, tumor biomarker responses 
were only seen in MSI-high tumors. Within the CRC 
group, MSI-high tumors treated with pembrolizumab had 
significantly improved PFS (not reached in the MSI-high 
group vs. 2.2 months in the MSI-low group) and OS (median 
OS not reached in the MSI-high group vs. 5 months in the 
MSI-low group). Furthermore, response to pembrolizumab 
correlated with higher number of mutations per tumor and 
higher intratumoral CD8+ CTL density (26). Based on this 
trial, pembrolizumab obtained.
FDA breakthrough designation in 2015 for use in MSI-high  
metastatic CRC
Based on the encouraging data above, there are now 
numerous checkpoint inhibitor-based trials ongoing 
targeting PD-1 and CTLA-4 (see Table 1). As an example, 
the CheckMate-142 trial is an ongoing randomized phase 
2 study of 59 patients with metastatic CRC evaluating 
nivolumab monotherapy (3 mg/kg every 2 weeks) vs. the 
combination nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) 
both given every 3 weeks. Patients were stratified by 
microsatellite instability of their tumors into microsatellite 
unstable (MSI-high) and microsatellite stable (non-MSI-
high). The dosing regimen of nivolumab 3 mg/kg and 
ipilimumab 1 mg/kg every 3 weeks was chosen based on 
Figure 2 A schematic overview of immunotherapy in GI cancers. There are many facets of immune-modulation effect an anti-tumor 
immune response in GI cancers, including adoptive cell transfer techniques, cytokine-based therapy, stromal modulation, vaccine-based 
therapy, and the most commonly used approach, checkpoint inhibitors. GI, gastrointestinal.
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toxicity assessment in a pilot cohort of non-MSI-high 
patients. Interim results show that a greater percentage of 
patients treated with nivolumab + ipilimumab have a tumor 
response (81% vs. 56% of patients) and have superior 
6 month PFS (66% vs. 46%). Adverse events were observed 
in 26% of the patients in the nivolumab + ipilimumab 
group, compared to 14% of patients in the nivolumab 
group. The most common adverse events were fatigue, 
diarrhea and pyrexia (27). Although the final analysis of this 
trial is awaited, the preliminary data suggest that dual PD-1 
and CTLA-4 checkpoint blockade is superior to PD-1 
blockade alone.
Given the impressive initial responses to checkpoint 
inhibitor therapy in MMR-deficient tumors, efforts have 
been underway to identify molecular features that predict 
response to immunotherapy, noting that responses are 
observed in non-MSI-high tumors as well, although 
at lower frequencies. A method to quantify the innate 
tumor immune response, the immunoscore, was recently 
developed by retrospectively analyzing patients treated with 
standard chemotherapy. The immunoscore was devised by 
quantifying the density of CTL (CD3+, CD8+) and memory 
T cells (CD3+, CD45RO+) both in the tumor core and in 
the invasive margin of the tumor, with scores ranging from 
0 (low-level immune infiltrate) to 4 (high-level immune 
infiltrate). By this method, the majority of tumors with high 
immunoscores are MSI-high, however a significant number 
of MSI-low tumors have high immunoscores. Importantly, 
higher immunoscore correlates with increased density of 
PD-1 and improved outcome when treated with standard 
chemotherapy. Moreover, immunoscore more strongly 
associates with outcome than MSI-status in patients 
undergoing standard chemotherapy. These data suggest that 
the superior outcome in high-immunoscore tumors is due 
to greater natural immune response, and predict that these 
tumors with higher immunoscores will be more responsive 
to immunotherapy. Prospective trials using immunotherapy 
in tumors stratified by immunoscore will be important to 
verify this approach as a predictive tool (28). 
Adoptive cell transfer therapy in CRC
Adoptive cell transfer is a technique whereby tumor-specific 
immune cells are isolated, expanded ex-vivo, then re-infused 
into the same host (autologous) or another host (allogeneic) 
following non-myeloablative lymphocyte conditioning, 
often using fludarabine/cyclophosphamide. This technique 
has been undertaken with both NK cells (innate immune 
system), and CD8+ T cells (adaptive immune system). 
The antigen specificity of adoptively transferred cells is 
often unknown. The source of autologous T cells may be 
either the tumor itself or a sentinel lymph node. A pilot 
study of adoptive cell transfer of sentinel lymph node-
derived autologous CD4+ Th1 cells in stage II–IV CRC was 
performed with promising results. Of the 9 patients with 
stage IV CRC in this study, 4 had a complete response, 1 
had a partial response, and 4 had stable disease. For the 9 
patients with stage IV disease, median OS was 2.6 years, 
compared to 0.8 years in controls; adverse effects were 
minimal (29). 
A recent study demonstrated the ability to use adoptively 
transferred TIL in metastatic colon cancer to specifically 
target a tumor-specific driver mutation (KRAS-G12D), 
a driver mutation that has been historically difficult to 
target. Briefly, in a single patient with KRAS-G12D-driven 
mCRC, TIL with antigen specificity to KRAS-G12D was 
harvested, ex-vivo expanded to approximately 1011 cells, 
then autologously re-infused. Forty days after infusion, 
all metastatic lesions had responded, a response that was 
maintained for 9 months. One isolated lesion displayed 
progression at the 9-month time point; however, this lesion 
was found to have loss of expression of the HLA-C allele to 
which the TIL were specific, thereby allowing for immune 
escape. This encouraging study demonstrates the feasibility 
and durability of adoptive T cell transfer in solid tumors (30).
Vaccine-based therapy in CRC
An additional approach to cancer immunotherapy 
involves vaccine-based strategies, such as tumor whole-
cell lysates, peptide vaccines and DC vaccines. Several 
early phase vaccine-based studies have been conducted 
in CRC targeting tumor-associated antigens, such as 
carcinoembryonic antigen (CEA). A recent phase 1/2 
trial enrolled 12 patients with non-metastatic CRC who 
underwent resection followed by 6 cycles of adjuvant 5-FU, 
who were then treated with tumor cell lysate-pulsed DC 
(n=6) or CEA-pulsed DC (n=6). Briefly, patients underwent 
leukapheresis to obtain immature DC, which were then 
cultured in the presence of the patient’s own tumor cell 
lysate or in the presence of CEA, with stimulatory cytokines 
to induce differentiation of DC 2.5×106 cells were then 
subcutaneously injected on days 0, 14, 48 and 56. After 
7 years of follow up, 6/6 patients treated with tumor lysate-
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pulsed DC were alive, but 3/6 patients treated with CEA-
pulsed DC died due to tumor relapse. There were no 
significant adverse events noted (31). Despite the small 
sample size of this study, the results are encouraging 
and warrant further randomized studies. A similar, but 
larger, study was done evaluating CEA- and MUC1-
expressing DC. Overall, 74 patients with mCRC underwent 
metastasectomy and adjuvant chemotherapy and were 
then randomly assigned to administration of autologous 
DC transfected with a CEA- and MUC1-expressing virus, 
versus administration of cell-free virus with GM-CSF. 
Overall, there was no significant difference in OS between 
the two treatment groups, however the two groups pooled 
has significantly better OS than controls (median OS not 
reached in vaccine group vs. 44.1 months in control group). 
Adverse events were mild, including fevers, myalgia and 
fatigue (32).
Esophageal and gastric cancers 
PD-1 and CTLA-4 based immunotherapy in GEJ cancer
PD-L1 is over-expressed in the majority of gastric cancers, 
but not in normal gastric epithelium, and higher expression 
of PD-L1 correlates with worse overall survival (33). 
Studies are currently underway investigating the role 
of anti-PD1 and anti-CTLA-4 therapies in gastric and 
GEJ cancer based on the association of their expression 
with survival. The KEYNOTE-012 trial is a phase 1b 
trial that evaluated pembrolizumab in 36 patients with 
PD-L1 positive advanced or metastatic gastric or GEJ 
adenocarcinoma. Of the 36 enrolled patients that were 
evaluable, 8 (22%) had a partial response, and a total of 
six grade 3–4 adverse events were documented by 5 (13%) 
of the patients, demonstrating that pembrolizumab has a 
reasonable toxicity profile and encouraging activity (34). 
The KEYNOTE-059, -061 and -062 trials are ongoing, 
and will further evaluate pembrolizumab in advanced 
gastric and GEJ adenocarcinoma. Other trials are 
currently ongoing evaluating the anti-PD-L1 antibody 
MEDI4736 (durvalumab) and the anti-CTLA-4 antibodies 
tremelimumab and ipilimumab (see Table 1). 
Adoptive cell transfer therapies in GEJ cancer
Adoptive cell transfer therapies are also being used in gastric 
and GEJ adenocarcinoma involving both T cells and NK 
cells. A recent study was performed using autologous ex-
vivo cytokine activated and expanded NK cells (CIK) as an 
adjuvant treatment for gastric cancer. Specifically, 151 patients 
that had undergone R0 D2 resected gastric cancer for stage 
IIIA–IV disease where treated with 6 cycles of adjuvant 5-FU, 
followed by at least 3 cycles of administration of autologous 
ex-vivo IFN-γ activated NK cells. Among patients with all 
histologic subtypes of gastric cancer, immunotherapy was 
associated with borderline improved median OS (48.1 vs. 
42.1 months, P=0.071), and significantly increased median 
DFS (40.4 vs. 34.1 months, P=0.044). Retrospectively 
stratifying patients by histologic subtype showed that 
patients with diffuse or mixed-type histology do not benefit 
from CIK therapy, however patients with intestinal-type 
tumors treated with CIK therapy have an improved 5-year 
OS (46.8% vs. 31.4%, P=0.045) and improved 5-year DFS 
(42.4% vs. 15.7%, P=0.023) (35).
A phase 1 pilot study of adoptive T cell transfer was 
done in patients with esophageal squamous cell carcinoma 
(recurrent or metastatic), targeting the commonly expressed 
MAGE-A4 antigen. Previous studies demonstrated that 
MAGE-A4 antigen is expressed in 52% of esophageal 
squamous cell carcinoma (36). Briefly, peripheral blood T 
cells were harvested by apheresis, infected with a retrovirus 
expressing a plasmid encoding MAGE-A4/HLA-A*24:02 
specific TCR α- and β-chains, then stimulated in vitro 
with MAGE-A4 peptide. Modified T cells (108–109) were 
re-infused without lymphodepletion conditioning; 2 and 
4 weeks after T cell infusion, patients received subcutaneous 
MAGE-A4 peptide vaccination. The transduced T cells 
were detectable in peripheral blood for approximately 
2 months in 7/10 patients, and retained ex vivo reactivity 
to MAGE-A4. The tumor responses were mixed, but with 
minimal toxicity, this study demonstrates the feasibility of 
the approach (37).
Hepatocellular carcinoma 
PD-1 and CTLA-4 based immunotherapy in HCC
HCC is a challenging malignancy due to frequently advanced 
disease at diagnosis and lack of highly effective therapy. 
Sorafenib is the only therapy approved to treat advanced 
HCC. Compared to placebo, sorafenib increases median 
OS from 7.9 to 10.7 months; it obtained FDA approval in 
2007 for treatment of advanced HCC based on this data (38). 
Due to the modest benefit with sorafenib, there has been 
increasing interest in immunotherapy as a treatment 
modality for HCC. The phase 1/2 CheckMate-040 study 
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was performed to evaluate the safety and preliminary efficacy 
of nivolumab (0.1–10 mg/kg) in advanced HCC. Of the 
51 patients enrolled, 73% had previously received sorafenib, 
and 76% had extra-hepatic disease. The disease control 
rate (in 48/51 evaluable patients) was 64%, with a median 
OS of 15.1 months. 20% of patients experienced grade 
3–4 treatment-related adverse events (39). Despite the 
small number of patients, these data compare favorably to 
sorafenib. Given these promising results, CheckMate-459, a 
phase 3 randomized trial of nivolumab vs. sorafenib as first-
line treatment of advanced HCC, is currently ongoing (40). 
The first study of an anti-CTLA-4 agent in HCC used 
tremelimumab in patients with HCC due to hepatitis C 
genotype 1b. Toxicity and anti-viral response was assessed 
in 20 patients; tumor response was assessed in 17 patients. 
Tremelimumab was administered at 90 mg/kg every 90 days. 
The overall disease control rate was 76%, with the most 
common grade ≥3 treatment-related adverse event being 
AST elevation (45% of patients), but was transient and was 
largely limited to cycle 1. The median OS was 8.2 months, 
similar to that seen with sorafenib (41).
Vaccine-based therapy in HCC 
Several small studies have been done in HCC using 
cytokines and adoptive cell transfer, including tumor lysate-
pulsed DC. However, these studies have seen limited 
success. A novel vaccine-based approach is currently 
underway in the European Union (EU); the HEPAVAC 
consortium. Briefly, the HEPAVAC consortium is 
developing a multi-target/multi-epitope peptide vaccine 
based on common MHC class I and class II tumor-
associated antigens expressed on HCC. Ideally, the vaccine 
will be used in a non-patient-specific manner with the 
option of a subsequent patient-specific vaccination (42). 
The HEPAVAC vaccine clinical trial was expected to start 
near the end of 2016. 
Pancreatic cancer 
Checkpoint inhibitor-based approaches in PDAC
There are no large studies of PD-1 or CTLA-4 based 
therapies in PDAC. However, there are numerous studies 
currently underway investigating anti-PD-1 agents 
(nivolumab and pembrolizumab) and anti-CTLA-4 agents 
(ipilimumab and tremelimumab) alone or combined with 
chemotherapy and radiation. A novel approach in PDAC 
addresses the desmoplastic stroma that creates a barrier to 
effective therapies. This approach relies on manipulation 
on the focal adhesion kinase (FAK) pathway using the 
small molecule FAK inhibitors VS-4718 or defactinib. In 
the KPC mouse model, the addition of the small molecule 
FAK inhibitor VS-4718 increased response to anti-PD1 
and anti-CTLA4 therapy combined with gemcitabine and 
significantly prolonged survival in the mouse (43). Based on 
this work, clinical trials using FAK inhibitors are currently 
underway. Additional approaches in PDAC include 
oncolytic viruses (such as Reolysin) with specificity for RAS-
activated tumors.  
Vaccine trails in PDAC
Vaccine trials in pancreatic cancer have shown exciting 
results in this difficult to treat disease. The two most 
promising vaccines in PDAC are the GVAX vaccine and 
CRS-207, often used together. GVAX is a pancreatic 
cancer cell line that expresses GM-CSF, while CRS-207 is 
a live-attenuated Listeria monocytogenes strain that expresses 
mesothelin. In combination, the two therapies induce T 
cell immunity against pancreatic cancer antigens such as 
mesothelin. The phase 2b Eclipse trial of GVAX + CRS-207 
showed promising interim results in metastatic pancreatic 
cancer (44), however, the final results are negative (data 
not yet published). Despite the negative results of Eclipse, 
the STELLAR trial is ongoing, randomizing patients with 
metastatic pancreatic cancer who have received one prior 
chemotherapy regimen to GVAX + CRS-207 ± nivolumab. 
Indoleamine 2,3 dioxygenase (IDO) in PDAC
IDO metabolizes tryptophan to the intermediate 
kynurenine, which is further metabolized, ultimately 
leading to production of NAD and ATP, with coincident 
depletion of tryptophan. Activation of this pathway leads 
to suppression of CTL via cell cycle arrest or anergy, 
and activates Tregs, overall facilitating tumor immune 
escape. IDO expression in lymphocytes is induced by 
inflammatory signals, including LPS and IFN-γ, in the 
tumor microenvironment. Additionally, IDO expression is 
inducible in tumor cells and APCs. Indoximod is a small 
molecule oral IDO inhibitor currently under evaluation in 
several clinical trials (45). Notably, a multi-institution phase 
2 trial of indoximod in combination with gemcitabine/
abraxane is currently underway in metastatic pancreatic 
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cancer, with interim results presented at ASCO 2016 
showing an objective response rate of 37% in 30 patients 
(NCT02077881) (46).
CCR2 modulation in PDAC
The CCR2/CCL2 chemokine pathway plays a critical 
role in recruiting immunosuppressive monocytes/
macrophages into the pancreatic cancer stroma. Pancreatic 
cancer secretes CCL2 to a greater extent than normal 
pancreas, which facilitates migration of CCR2+ blood 
and bone marrow monocytes into the pancreatic tumor 
stroma. In resected pancreatic cancer, a shift in CCR2+ 
monocyte distribution from bone marrow to blood (i.e., 
a higher ratio of peripheral blood: bone marrow CCR2+ 
monocytes) predicts worse survival. Therefore, inhibition of 
the CCR2/CCL2 signaling pathway is predicted to improve 
innate anti-tumor immune responses by attenuating the 
immunosuppressive TME and thereby improve survival (47). 
In a phase 1b trial of borderline resectable and locally 
advanced PDAC, the small molecule CCR2 inhibitor 
PF-04136309, in combination with FOLFIRINOX, 
was safe and tolerable, and displayed an objective tumor 
response of 49% (16/33 patients), compared to zero of five 
patients treated with FOLFIRINOX alone. As expected, 
the addition of PF-04136309 resulted in a re-distribution of 
CCR2-positive monocytes from the peripheral blood to the 
bone marrow compartment (the opposite of that seen with 
FOLFIRINOX alone) and an approximate 4-fold decrease 
in the number of tumor-associated macrophages (TAM), 
a 2-fold increase in the number of CD4+ and CD8+ T cells, 
and nearly a 6-fold decrease in the number of Tregs in 
tumors compared to FOLFIRINOX alone (48). This work 
lays the foundation for further investigation into CCR2 
modulation in pancreatic cancer.
Conclusions
The initial observation suggesting that the immune system 
may play a role in modulating cancers was made nearly 
125 years ago (49). Over the last two decades, our 
understanding of the basic mechanisms underlying 
immune modulation has greatly improved, allowing for the 
development of multiple exciting therapeutic approaches 
for immunomodulation of tumors. The challenges moving 
forward are not only to fine-tune these various immune-
based approaches, but also learn how to appropriately 
integrate them with molecularly targeted agents (such as 
TKIs, angiogenesis inhibitors, etc.) as well as cytotoxic 
chemotherapy. 
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